NASDAQ:APTOAptose Biosciences Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Aptose Biosciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $5.06 -0.06 (-1.17 %) (As of 07/31/2020 04:00 PM ET) Add Compare Share Today's Range$5.00Now: $5.06▼$5.2150-Day Range$4.93MA: $6.09▼$6.9752-Week Range$1.82Now: $5.06▼$9.25Volume1.04 million shsAverage Volume1.27 million shsMarket Capitalization$386.08 millionP/E RatioN/ADividend YieldN/ABeta1.52 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingAptose Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $11.40, Aptose Biosciences has a potential upside of 125.3% from its current price of $5.06.Amount of Analyst CoverageAptose Biosciences has only been the subject of 4 research reports in the past 90 days. Previous Next 2.7 Community Rank Outperform VotesAptose Biosciences has received 343 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAptose Biosciences has received 285 “underperform” votes. (Add your “underperform” vote.)Community SentimentAptose Biosciences has received 54.62% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Aptose Biosciences and other stocks. Vote “Outperform” if you believe APTO will outperform the S&P 500 over the long term. Vote “Underperform” if you believe APTO will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAptose Biosciences does not currently pay a dividend.Dividend GrowthAptose Biosciences does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aptose Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,429,061.00 in company stock.Percentage Held by InsidersOnly 7.34% of the stock of Aptose Biosciences is held by insiders.Percentage Held by Institutions39.38% of the stock of Aptose Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Aptose Biosciences are expected to decrease in the coming year, from ($0.65) to ($0.76) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aptose Biosciences is -9.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aptose Biosciences is -9.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAptose Biosciences has a P/B Ratio of 4.11. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.44 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:APTO Previous Symbol CUSIPN/A CIK882361 Webwww.aptose.com Phone64-7479-9828Debt Debt-to-Equity RatioN/A Current Ratio20.56 Quick Ratio20.56Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.23 per share Price / Book4.11Profitability EPS (Most Recent Fiscal Year)($0.52) Net Income$-26,280,000.00 Net MarginsN/A Return on Equity-53.31% Return on Assets-48.99%Miscellaneous Employees31 Outstanding Shares76,300,000Market Cap$386.08 million Next Earnings Date8/4/2020 (Confirmed) OptionableOptionable $5.06 -0.06 (-1.17 %) (As of 07/31/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive APTO News and Ratings via Email Sign-up to receive the latest news and ratings for APTO and its competitors with MarketBeat's FREE daily newsletter. Aptose Biosciences (NASDAQ:APTO) Frequently Asked Questions How has Aptose Biosciences' stock been impacted by COVID-19 (Coronavirus)? Aptose Biosciences' stock was trading at $5.84 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, APTO shares have decreased by 13.4% and is now trading at $5.06. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Aptose Biosciences? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aptose Biosciences in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Aptose Biosciences. When is Aptose Biosciences' next earnings date? Aptose Biosciences is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Aptose Biosciences. How can I listen to Aptose Biosciences' earnings call? Aptose Biosciences will be holding an earnings conference call on Tuesday, August 4th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available. How were Aptose Biosciences' earnings last quarter? Aptose Biosciences Inc. (NASDAQ:APTO) released its quarterly earnings results on Tuesday, May, 5th. The biotechnology company reported ($0.15) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.10) by $0.05. View Aptose Biosciences' earnings history. What price target have analysts set for APTO? 5 equities research analysts have issued 12-month price objectives for Aptose Biosciences' shares. Their forecasts range from $9.00 to $16.00. On average, they expect Aptose Biosciences' stock price to reach $11.40 in the next twelve months. This suggests a possible upside of 125.3% from the stock's current price. View analysts' price targets for Aptose Biosciences. Has Aptose Biosciences been receiving favorable news coverage? Media headlines about APTO stock have trended negative recently, InfoTrie Sentiment Analysis reports. The research group ranks the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Aptose Biosciences earned a media sentiment score of -2.2 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View the latest news about Aptose Biosciences. Are investors shorting Aptose Biosciences? Aptose Biosciences saw a increase in short interest in the month of July. As of July 15th, there was short interest totaling 1,770,000 shares, an increase of 9.9% from the June 30th total of 1,610,000 shares. Based on an average daily trading volume, of 877,600 shares, the short-interest ratio is currently 2.0 days. Currently, 2.2% of the shares of the stock are sold short. View Aptose Biosciences' Current Options Chain. Who are some of Aptose Biosciences' key competitors? Some companies that are related to Aptose Biosciences include Sangamo Therapeutics (SGMO), Legend Biotech (PCVX), Bill.com (RVMD), Forma Therapeutics (FMTX), NanoString Technologies (NSTG), Adverum Biotechnologies (ADVM), Coherus Biosciences (CHRS), Alector (ALEC), Regenxbio (RGNX), Adaptimmune Therapeutics (ADAP), Cortexyme (CRTX), Nantkwest (NK), Vaxart (VXRT), I-Mab (BDTX) and Beam Therapeutics (BEAM). View all competitors. What other stocks do shareholders of Aptose Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aptose Biosciences investors own include Aurinia Pharmaceuticals (AUPH), Aurora Cannabis (ACB), NVIDIA (NVDA), Arch Therapeutics (ARTH), Canopy Growth (CGC), Micron Technology (MU), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Anavex Life Sciences (AVXL) and CymaBay Therapeutics (CBAY). Who are Aptose Biosciences' key executives? Aptose Biosciences' management team includes the following people: Dr. William G. Rice Ph.D., Chairman, Pres & CEO (Age 59)Mr. Gregory K. Chow CPA, MBA, BA, Sr. VP, CFO & Principal Accounting Officer (Age 45)Mr. Ernest Kitt B.S., M.S, VP of Devel. & Technical OperationsDr. Stephen B. Howell, Chief Medical Officer (Age 73)Mr. Peter Murray, Director of Clinical Devel. What is Aptose Biosciences' stock symbol? Aptose Biosciences trades on the NASDAQ under the ticker symbol "APTO." Who are Aptose Biosciences' major shareholders? Aptose Biosciences' stock is owned by a number of institutional and retail investors. Top institutional investors include Sigma Planning Corp (0.32%) and Patriot Financial Group Insurance Agency LLC (0.14%). Company insiders that own Aptose Biosciences stock include Erich Platzer, Gregory K Chow, Jotin Marango, Warren Whitehead and William G Rice. View institutional ownership trends for Aptose Biosciences. Which major investors are selling Aptose Biosciences stock? APTO stock was sold by a variety of institutional investors in the last quarter, including Patriot Financial Group Insurance Agency LLC. Company insiders that have sold Aptose Biosciences company stock in the last year include Gregory K Chow, Jotin Marango, Warren Whitehead, and William G Rice. View insider buying and selling activity for Aptose Biosciences. Which major investors are buying Aptose Biosciences stock? APTO stock was bought by a variety of institutional investors in the last quarter, including Sigma Planning Corp. Company insiders that have bought Aptose Biosciences stock in the last two years include Gregory K Chow, and William G Rice. View insider buying and selling activity for Aptose Biosciences. How do I buy shares of Aptose Biosciences? Shares of APTO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Aptose Biosciences' stock price today? One share of APTO stock can currently be purchased for approximately $5.06. How big of a company is Aptose Biosciences? Aptose Biosciences has a market capitalization of $386.08 million. The biotechnology company earns $-26,280,000.00 in net income (profit) each year or ($0.52) on an earnings per share basis. Aptose Biosciences employs 31 workers across the globe. What is Aptose Biosciences' official website? The official website for Aptose Biosciences is www.aptose.com. How can I contact Aptose Biosciences? Aptose Biosciences' mailing address is 251 CONSUMERS ROAD SUITE 1105, TORONTO A6, M2J 4R3. The biotechnology company can be reached via phone at 64-7479-9828 or via email at [email protected] This page was last updated on 8/3/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
